The purpose of this study is to investigate the following:

• If a new immune stimulating experimental drug, N-803, is safe and tolerable
• If a combination of N-803 and two new experimental drugs that are antibodies to HIV, VRC07-523LS and 10-1074, is safe and tolerable
• How well HIV is controlled after stopping ART in persons who received N-803 alone compared to N-803 with VRC07-523LS and 10-1074

This study involves study treatment with N-803 alone or in combination with VRC07-523LS and 10-1074. N-803 is an immune stimulating experimental drug that binds to the interleukin 15 (also known as “IL-15”) receptor. IL-15 is a naturally occurring substance produced by the body to stimulate cells of the immune system to increase in number and become more active. VRC07-523LS and 10-1074 are antibodies to HIV and are also experimental drugs. Antibodies are one of the ways the human body fights infection. Antibodies are natural proteins that the body can make to prevent infectious agents such as bacteria and viruses from making you sick. Researchers can also make antibodies in laboratories and give them to people through a vein (with an IV). These antibodies attach to HIV and can block HIV from attacking cells in the body and from spreading to other parts of the body. These antibodies are being developed to potentially treat and prevent HIV infection.